The American Arbitration Association Tribunal has dismissed claims from France’s Adocia (Euronext: ADOC) that Eli Lilly (NYSE: LLY) misappropriated and misused company secrets.
The tribunal also blocked a countersuit from Lilly, stating that Adocia concealed the relevant discoveries and confidential information at the heart of the claims.
The decision should mark the final twist in a long-running legal dispute between the firms, arising from a collaborative research and license agreement in the area of diabetes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze